PMID- 35387559
OWN - NLM
STAT- MEDLINE
DCOM- 20220408
LR  - 20220531
IS  - 1744-5116 (Electronic)
IS  - 1388-0209 (Print)
IS  - 1388-0209 (Linking)
VI  - 60
IP  - 1
DP  - 2022 Dec
TI  - Gut microbiota and metabonomics used to explore the mechanism of Qing'e Pills in 
      alleviating osteoporosis.
PG  - 785-800
LID - 10.1080/13880209.2022.2056208 [doi]
AB  - CONTEXT: The traditional Chinese medicine Qing'e Pills (QEP) has been used to 
      treat postmenopausal osteoporosis (PMO). OBJECTIVE: We evaluated the regulatory 
      effects of QEP on gut microbiota in osteoporosis. MATERIALS AND METHODS: Eighteen 
      female SD rats were divided into three groups: sham surgery (SHAM), 
      ovariectomized (OVX) and ovariectomized treated with QEP (OVX + QEP). Six weeks 
      after ovariectomy, QEP was administered to OVX + QEP rats for eight weeks 
      (4.5 g/kg/day, i.g.). After 14 weeks, the bone microstructure was evaluated. 
      Differences in gut microbiota were analysed via 16S rRNA gene sequencing. Changes 
      in endogenous metabolites were studied using UHPLC-Q-TOF/MS technology. GC-MS was 
      used to detect short-chain fatty acids. Furthermore, we measured serum 
      inflammatory factors, such as IL-6, TNF-alpha and IFN-gamma, which may be related to gut 
      microbiota. RESULTS: OVX + QEP exhibited increased bone mineral density 
      (0.11 +/- 0.03 vs. 0.21 +/- 0.02, p< 0.001) compared to that of OVX. QEP altered the 
      composition of gut microbiota. We identified 19 potential biomarkers related to 
      osteoporosis. QEP inhibited the elevation of TNF-alpha (38.86 +/- 3.19 vs. 
      29.43 +/- 3.65, p< 0.05) and IL-6 (83.38 +/- 16.92 vs. 45.26 +/- 3.94, p< 0.05) levels, 
      while it increased the concentrations of acetic acid (271.95 +/- 52.41 vs. 
      447.73 +/- 46.54, p< 0.001), propionic acid (28.96 +/- 5.73 vs. 53.41 +/- 14.26, 
      p< 0.01) and butyric acid (24.92 +/- 18.97 vs. 67.78 +/- 35.68, p< 0.05). 
      CONCLUSIONS: These results indicate that QEP has potential of regulating 
      intestinal flora and improving osteoporosis. The combination of anti-osteoporosis 
      drugs and intestinal flora could become a new treatment for osteoporosis.
FAU - Xie, Hui
AU  - Xie H
AUID- ORCID: 0000-0002-8083-4616
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
AD  - Jiangsu Key Laboratory of Chinese Medicine Processing, Engineering Center of 
      State Ministry of Education for Standardization of Chinese Medicine Processing, 
      Nanjing University of Chinese Medicine, Nanjing, China.
FAU - Hua, Zhengying
AU  - Hua Z
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
AD  - Jiangsu Key Laboratory of Chinese Medicine Processing, Engineering Center of 
      State Ministry of Education for Standardization of Chinese Medicine Processing, 
      Nanjing University of Chinese Medicine, Nanjing, China.
FAU - Guo, Mengyu
AU  - Guo M
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
AD  - Jiangsu Key Laboratory of Chinese Medicine Processing, Engineering Center of 
      State Ministry of Education for Standardization of Chinese Medicine Processing, 
      Nanjing University of Chinese Medicine, Nanjing, China.
FAU - Lin, Shangyang
AU  - Lin S
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
AD  - Jiangsu Key Laboratory of Chinese Medicine Processing, Engineering Center of 
      State Ministry of Education for Standardization of Chinese Medicine Processing, 
      Nanjing University of Chinese Medicine, Nanjing, China.
FAU - Zhou, Yaqian
AU  - Zhou Y
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
AD  - Jiangsu Key Laboratory of Chinese Medicine Processing, Engineering Center of 
      State Ministry of Education for Standardization of Chinese Medicine Processing, 
      Nanjing University of Chinese Medicine, Nanjing, China.
FAU - Weng, Zebin
AU  - Weng Z
AD  - School of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, 
      China.
FAU - Wu, Li
AU  - Wu L
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
FAU - Chen, Zhipeng
AU  - Chen Z
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
AD  - Jiangsu Key Laboratory of Chinese Medicine Processing, Engineering Center of 
      State Ministry of Education for Standardization of Chinese Medicine Processing, 
      Nanjing University of Chinese Medicine, Nanjing, China.
FAU - Xu, Zisheng
AU  - Xu Z
AD  - Wuhu Pure Sunshine Natural Medicine Company Limited, Wuhu, China.
FAU - Li, Weidong
AU  - Li W
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
AD  - Jiangsu Key Laboratory of Chinese Medicine Processing, Engineering Center of 
      State Ministry of Education for Standardization of Chinese Medicine Processing, 
      Nanjing University of Chinese Medicine, Nanjing, China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Pharm Biol
JT  - Pharmaceutical biology
JID - 9812552
RN  - 0 (Interleukin-6)
RN  - 0 (RNA, Ribosomal, 16S)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Animals
MH  - Bone Density
MH  - Female
MH  - *Gastrointestinal Microbiome
MH  - Interleukin-6
MH  - Metabolomics
MH  - *Osteoporosis/drug therapy
MH  - Ovariectomy
MH  - RNA, Ribosomal, 16S
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Tumor Necrosis Factor-alpha/pharmacology
PMC - PMC9004512
OTO - NOTNLM
OT  - Traditional Chinese medicine
OT  - intestinal flora
OT  - mass spectrometry
OT  - postmenopausal
COIS- The authors declare that there are no conflicts of interest associated with this 
      publication.
EDAT- 2022/04/08 06:00
MHDA- 2022/04/09 06:00
PMCR- 2022/04/06
CRDT- 2022/04/07 05:26
PHST- 2022/04/07 05:26 [entrez]
PHST- 2022/04/08 06:00 [pubmed]
PHST- 2022/04/09 06:00 [medline]
PHST- 2022/04/06 00:00 [pmc-release]
AID - 2056208 [pii]
AID - 10.1080/13880209.2022.2056208 [doi]
PST - ppublish
SO  - Pharm Biol. 2022 Dec;60(1):785-800. doi: 10.1080/13880209.2022.2056208.